Graphene is gaining serious traction in Europe after major funding, while in Australia, Adisyn is positioning itself as a key ...

Neuren Pharmaceuticals and its US partner Acadia have been blitzing it with the Rett syndrome treatment Daybue.

Donald Trump considers the pinnacle of his ‘Make America Great Again’ pledge a US-made iPhone. This is an unlikely outcome and here's why.

ASX nudges up on US tariff hopes, but Bellevue Gold gets hammered after a capital raise, while HUB24 shines with record inflows.

Donald Trump again has raised the prospect of a new tariff on imported pharmaceuticals, reportedly pitched at a 25% rate.

Climbing energy and gold stocks have lifted the ASX in early trading, boosting the bourse 0.3pc in the first hour.

Meteoric (ASX:MEI) has added tonnes to its Brazilian portfolio, making it one of the highest grade ionic clay rare earth deposits globally.

Tony turns his attention to pivotal phase 3 trials and what mix of make or break biotechs you should have in your portfolio.

Several ASX companies are developing and providing technologies for reliable communications in remote areas, including Harvest Technology.

MPK (ASX:MPK) has started phase 2 diamond drilling at Ferké in Côte d’Ivoire testing extensions to high-grade mineralisation at Ouarigue.

Australian Mines (ASX:AUZ) will expand a scoping study on its Flemington project as China tightens its grip on scandium exports.

The US FDA has approved EBR System's leadless pacemaker WISE, the only heart device able to deliver left-ventricle ...